CINCINNATI, Aug. 31 Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today appointed Mark J. Roseman, D.Sc., as the Company's new Senior Vice President and Chief Marketing Officer (CMO), effective immediately. Dr. Roseman brings to Kendle more than 20 years of senior operations leadership and strategic account development experience in the clinical services industry and will have executive-level responsibility for the Company's worldwide sales and strategic partnership development efforts. He will report directly to Chairman and CEO Candace Kendle, PharmD, and will serve on the Company's Executive Committee. Dr. Roseman assumes the Senior Vice President and CMO role from Simon Higginbotham who will transition to an external consulting role providing strategic marketing and business development support services for the Company.
"Mark brings to Kendle a wealth of operational experience and proven sales success in the CRO industry," said Dr. Kendle. "We look forward to his leadership as we drive continued growth in sales and strengthen Kendle's position as a multinational top-tier CRO and strategic partner of choice for our customers."
Dr. Roseman joins Kendle from i3 Research where he was Vice President, Business Operations. His experience includes nearly 13 years with PPD, Inc., where he served most recently as Vice President, Account Management, with responsibility for key customer accounts. Previously, Dr. Roseman was Vice President, Clinical Operations, for PPD responsible for all clinical operations activities in the Wilmington, N.C., and Research Triangle Park offices with oversight of more than 1,100 employees. In this role he provided leadership for the centralized study start-up group as well as the oncology, cardiovascular, anti-viral/anti-infectives, respiratory, ophthalmology, critical care and general medicine divisions. While at PPD Dr. Roseman served on the company's governance and executive relationship committees for multiple strategic customers. Prior to joining PPD he spent six years with CIBA Vision Corporation in Duluth, Ga., holding several positions of increasing responsibility in the area of ophthalmic clinical research.
"I look forward to contributing to Kendle's future growth and success as a leading drug development partner," said Dr. Roseman. "The long-term outlook for outsourcing remains strong, and I am committed to furthering Kendle's focus on delivery of best-in-class solutions across early- to late-stage clinical development that increase efficiencies in the drug development process and create value for our customers."
Dr. Roseman holds a Doctor of Science in epidemiology and a Master of Public Health in biostatistics and epidemiology from Boston University School of Public Health, a Doctor of Optometry and a Master of Science in physiological optics from The Ohio State University College of Optometry, and a Bachelor of Science in engineering physics from Miami University in Oxford, Ohio. He will be based out of Kendle's Durham, N.C. office.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.
SOURCE Kendle International Inc.